Latest developments in MUC1 immunotherapy

Biochemical Society Transactions - Tập 46 Số 3 - Trang 659-668 - 2018
Joyce Taylor‐Papadimitriou1, Joy Burchell1, Rosalind Graham1, Richard Beatson1
1Breast Cancer Biology Lab, School of Cancer and Pharmaceutical Sciences, King's College London, London, U.K.

Tóm tắt

Currently, there is renewed interest in attempting to recruit the host immune system to eliminate cancers, and within this renewed activity, MUC1 continues to arouse interest. MUC1 has been considered a possible therapeutic target for the past 30 years as it is up-regulated, aberrantly glycosylated and its polarization is lost in many adenocarcinomas. Moreover, MUC1 is expressed by some haematopoietic cancers, including acute myeloid leukaemia and myeloma. Although multiple clinical trials have been initiated and immune responses have been documented, effective clinical benefit worthy of approval for general application has not as yet been achieved. However, this does not appear to have quelled the interest in MUC1 as a therapeutic target, as shown by the increase in the number of MUC1-based clinical trials initiated in 2017 (Figure 1). As with all translational studies, incorporating new relevant research findings into therapeutic strategy is difficult. Decisions are made to commit to a specific strategy based on the information and data available when the trial is initiated. However, the time required for preclinical studies and early trials can render the founding concept not always appropriate for proceeding to a larger definitive trial. Here, we summarize the attempts made, to date, to bring MUC1 into the world of cancer immunotherapy and discuss how research findings regarding MUC1 structure and function together with expanded knowledge of its interactions with the tumour environment and immune effector cells could lead to improved therapeutic approaches.Figure 1.Number of MUC1-targeted trials initiated each year.

Từ khóa


Tài liệu tham khảo

Gendler, 1987, Cloning a cDNA coding for differentiation and tumour-associated mucin glycoprotein expressed by human mammary epithelium, Proc. Natl Acad. Sci. U.S.A., 84, 6060, 10.1073/pnas.84.17.6060

Lan, 1990, Cloning and sequencing of a human pancreatic tumor mucin cDNA, J. Biol. Chem., 265, 15294, 10.1016/S0021-9258(18)77255-4

Ligtenberg, 1990, Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini, J. Biol. Chem., 265, 5573, 10.1016/S0021-9258(19)39399-8

Siddiqui, 1988, Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen, Proc. Natl Acad. Sci. U.S.A., 85, 2320, 10.1073/pnas.85.7.2320

Baruch, 1999, The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein, Cancer Res., 59, 1552

Julian,, 2009, MUC1 is a substrate for γ-secretase, J. Cell Biochem., 108, 802, 10.1002/jcb.22292

Kufe,, 2013, MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches, Oncogene, 32, 1073, 10.1038/onc.2012.158

Kufe,, 2009, Mucins in cancer: function, prognosis and therapy, Nat. Rev. Cancer, 9, 874, 10.1038/nrc2761

Taylor-Papadimitriou, 1981, Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture, Int. J. Cancer, 28, 17, 10.1002/ijc.2910280104

Hilkens,, 1984, Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors, Int. J. Cancer, 34, 197, 10.1002/ijc.2910340210

Taylor-Papadimitriou, 1991, Report on the first international workshop on carcinoma-associated mucins, Int. J. Cancer, 49, 1, 10.1002/ijc.2910490102

Rye, 1998, ISOBM TD-4 International workshop on monoclonal antibodies against MUC1

Arklie, 1981, Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers, Int. J. Cancer, 28, 23, 10.1002/ijc.2910280105

Kufe,, 1984, Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors, Hybridoma, 3, 223, 10.1089/hyb.1984.3.223

Lloyd, 1996, Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells, J. Biol. Chem., 271, 33325, 10.1074/jbc.271.52.33325

Bäckström, 2003, Recombinant MUC1 mucin with a breast cancer-like-O-glycosylation produced in large amounts of Chinese-hamster ovary cells, Biochem. J., 376, 677, 10.1042/bj20031130

Burchell, 1987, Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin, Cancer Res., 47, 5476

Perey,, 1992, Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen, Cancer Res., 52, 2563

Rivalland,, 2015, Update on Mucin-1 immunotherapy in cancer: a clinical perspective, Expert Opin. Biol. Ther., 15, 1773, 10.1517/14712598.2015.1088519

Butts,, 2014, Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial, Lancet Oncol., 15, 59, 10.1016/S1470-2045(13)70510-2

Quoix,, 2016, TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, Lancet Oncol., 17, 212, 10.1016/S1470-2045(15)00483-0

Torch,, 2017, Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC, J. Immunother. Cancer, 5, 70, 10.1186/s40425-017-0274-x

https://clinicaltrials.gov/ct2/show/NCT02823990

Mitchell,, 2014, A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer, J. Immunother. Cancer, 2, 16, 10.1186/2051-1426-2-16

Gray,, 2014, . Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy, J. Clin. Oncol., 32, 5504, 10.1200/jco.2014.32.15_suppl.5504

Lepisto,, 2008, A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors, Cancer Ther., 6, 955

Wierecky,, 2006, Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients, Cancer Res., 66, 5910, 10.1158/0008-5472.CAN-05-3905

Gong,, 1998, Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells, Proc. Natl Acad. Sci. U.S.A., 95, 6279, 10.1073/pnas.95.11.6279

Rosenblatt,, 2016, Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions, Sci. Transl. Med., 8, 368ra171, 10.1126/scitranslmed.aag1298

Rittig,, 2011, Intradermal vaccinations with
RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients, Mol. Ther., 19, 990, 10.1038/mt.2010.289

Morse,, 2013, A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer, Ann. Surg., 258, 879, 10.1097/SLA.0b013e318292919e

Vassilaros,, 2013, Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1, Immunotherapy, 5, 1177, 10.2217/imt.13.126

Shindo,, 2014, Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer, J. Transl. Med., 12, 175, 10.1186/1479-5876-12-175

Jerome,, 1991, Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells, Cancer Res., 51, 2908

Gaidzik,, 2013, The development of synthetic antitumour vaccines from mucin glycopeptide antigens, Chem. Soc. Rev., 42, 4421, 10.1039/c3cs35470a

Kaiser,, 2010, Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2, Angew. Chem. Int. Ed. Engl., 49, 3688, 10.1002/anie.201000462

Palitzsch,, 2016, A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer, Angew. Chem. Int. Ed. Engl., 55, 2894, 10.1002/anie.201509935

Stergiou,, 2017, Immunization with a synthetic human MUC1 glycopeptide vaccine against tumor-associated MUC1 breaks tolerance in human MUC1 transgenic mice, ChemMedChem., 12, 1424, 10.1002/cmdc.201700387

Mony,, 2015, Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model, Cancer Immunol. Immunother, 64, 1095, 10.1007/s00262-015-1712-6

Haurum,, 1994, Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes, J. Exp. Med., 180, 739, 10.1084/jem.180.2.739

Karsten,, 2004, Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1), Glycobiology, 14, 681, 10.1093/glycob/cwh090

Danielczyk,, 2006, Pankomab: a potent new generation anti-tumour MUC1 antibody, Cancer Immunol. Immunother., 55, 1337, 10.1007/s00262-006-0135-9

Fiedler,, 2016, A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas, Eur. J. Cancer, 63, 55, 10.1016/j.ejca.2016.05.003

Wilkie,, 2008, Retargeting of human T cells to tumour-associated MUC1: the evolution of a chimeric antigen receptor, J. Immunol., 180, 4901, 10.4049/jimmunol.180.7.4901

Posey, 2016, Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma, Immunity, 44, 1444, 10.1016/j.immuni.2016.05.014

Sørensen, 2006, Chemoenzymatically synthesized multimeric Tn/STn-MUC1 glycopeptides elicit cancer specific anti-MUC1 antibody responses and override tolerance, Glycobiology, 16, 96, 10.1093/glycob/cwj044

Tarp, 2007, Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat, Glycobiology, 17, 197, 10.1093/glycob/cwl061

Correa, 2003, Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T cell migration, Immunology, 108, 32, 10.1046/j.1365-2567.2003.01562.x

Gavrill, A. (2017) Chimeric Antigen Receptor (CAR) T-cell Immunotherapy for MUC1-positive Breast CancerPhD Thesis, Kings College London

Vlad,, 2002, Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells, J. Exp. Med., 196, 1435, 10.1084/jem.20020493

Ryan,, 2009, Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice, Biol. Chem., 390, 611, 10.1515/BC.2009.070

Scheid,, 2016, Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer, Cancer Immunol. Res., 4, 881, 10.1158/2326-6066.CIR-15-0189

Beatson,, 2016, The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9, Nat. Immunol., 17, 1273, 10.1038/ni.3552

Pyzer,, 2017, MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia, Blood, 129, 1791, 10.1182/blood-2016-07-730614

Rajabi,, 2017, MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas, Biochim. Biophys. Acta, 1868, 117, 10.1016/j.bbcan.2017.03.003

Tagde,, 2016, MUC1-C drives MYC in multiple myeloma, Blood, 127, 2587, 10.1182/blood-2015-07-659151

Tagde,, 2017, Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma, Oncotarget, 8, 69237, 10.18632/oncotarget.20144

Bouillez,, 2017, MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer, Oncogene, 36, 4037, 10.1038/onc.2017.47

Bouillez,, 2017, MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer, Oncoimmunology, 6, e1338998, 10.1080/2162402X.2017.1338998

Pyzer,, 2017, MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs, Leukemia, 31, 2780, 10.1038/leu.2017.163

Maeda,, 2018, MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer, Cancer Res., 78, 205, 10.1158/0008-5472.CAN-17-1636

Miles,, 2011, Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer, Oncologist, 16, 1092, 10.1634/theoncologist.2010-0307

Verheijen,, 2006, Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission, J. Clin. Oncol., 24, 571, 10.1200/JCO.2005.02.5973

Thông tin
Thông tin xuất bản

Biochemical Society Transactions

Tập 46 Số 3

659-668

Thông tin tác giả